Table 2.
Effect of treatments on total symptom (T7SS), nasal symptom (T4NSS), and non-nasal symptom (T3NNSS) scores in the ITT population at 4 weeks
| Placebo (N=122) | Rupatadine 10 mg (N=117) | Desloratadine 5 mg (N=117) | P-value (ANOVA) | |
|---|---|---|---|---|
| T7SS [mean (SD)] | ||||
| Reflective values | 8.79 (4.13) | 7.42 (3.70) | 6.99 (4.88) | |
| Change from baseline | –5.22 (4.21) | -6.35 (3.83) | -6.69 (3.89) | 0.002* |
| % change from baseline | -37.3 | -46.1 | -48.9 | |
| Instantaneous values | 8.34 (4.37) | 7.09 (3.59) | 6.72 (4.23) | |
| Change from baseline | -4.49 (4.30) | -5.83 (3.93) | -5.94 (3.99) | 0.010 |
| % change from baseline | -35.1 | -45.2 | -46.8 | |
| T4NSS [mean (SD)] | ||||
| Reflective values | 5.56 (2.46) | 4.84 (2.23) | 4.68 (2.64) | |
| Change from baseline | -3.10 (2.50) | -3.69 (2.34) | -3.90 (2.43) | 0.029 |
| % change from baseline | -35.8 | -43.2 | -45.4 | |
| Instantaneous values | 5.28 (2.63) | 4.61 (2.26) | 4.45 (2.50) | |
| Change from baseline | -2.60 (2.50) | -3.42 (2.39) | -3.47 (2.41) | 0.010 |
| % change from baseline | -33.2 | -42.6 | -43.8 | |
| T3NNSS [mean (SD)] | ||||
| Reflective values | 3.23 (1.94) | 2.59 (1.68) | 2.31 (1.91) | |
| Change from baseline | -2.13 (1.96) | -2.66 (1.66) | -2.79 (1.72) | 0.009 |
| % change from baseline | -39.6 | -50.6 | -54.7 | |
| Instantaneous values | 3.08 (2.01) | 2.48 (1.56) | 2.26 (1.91) | |
| Change from baseline | -1.88 (2.05) | -2.41 (1.75) | -2.46 (1.86) | 0.029 |
| % change from baseline | -37.9 | -49.3 | -52.2 | |
Note:P-value obtained with ANCOVA adjusted by treatment, country, and baseline values.
Abbreviations: T7SS, total seven symptoms score; T4NSS, total four nasal symptoms score; T3NNSS, total three nonnasal symptoms score; ITT, intention to treat; N, number; ANOVA, analysis of variance; SD, standard deviation; ANCOVA, analysis of covariance.